Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SOX2 regulates the hypothalamic-pituitary axis at multiple levels
Sujatha A. Jayakody, … , Mehul T. Dattani, Juan P. Martinez-Barbera
Sujatha A. Jayakody, … , Mehul T. Dattani, Juan P. Martinez-Barbera
Published September 4, 2012
Citation Information: J Clin Invest. 2012;122(10):3635-3646. https://doi.org/10.1172/JCI64311.
View: Text | PDF
Research Article Development

SOX2 regulates the hypothalamic-pituitary axis at multiple levels

  • Text
  • PDF
Abstract

Sex-determining region Y (SRY) box 2 (SOX2) haploinsufficiency causes a form of hypopituitarism in humans that is characterized by gonadotrophin deficiency known as hypogonadotrophic hypogonadism. Here, we conditionally deleted Sox2 in mice to investigate the pathogenesis of hypogonadotrophic hypogonadism. First, we found that absence of SOX2 in the developing Rathke pouch of conditional embryos led to severe anterior lobe hypoplasia with drastically reduced expression of the pituitary-specific transcription factor POU class 1 homeobox 1 (POU1F1) as well as severe disruption of somatotroph and thyrotroph differentiation. In contrast, corticotrophs, rostral-tip POU1F1-independent thyrotrophs, and, interestingly, lactotrophs and gonadotrophs were less affected. Second, we identified a requirement for SOX2 in normal proliferation of periluminal progenitors; in its absence, insufficient precursors were available to produce all cell lineages of the anterior pituitary. Differentiated cells derived from precursors exiting cell cycle at early stages, including corticotrophs, rostral-tip thyrotrophs, and gonadotrophs, were generated, while hormone-producing cells originating from late-born precursors, such as somatotrophs and POU1F1-dependent thyrotrophs, were severely reduced. Finally, we found that 2 previously characterized patients with SOX2 haploinsufficiency and associated hypogonadotrophic hypogonadism had a measurable response to gonadotropin-releasing hormone (GnRH) stimulation, suggesting that it is not the absence of gonadotroph differentiation, but rather the deficient hypothalamic stimulation of gonadotrophs, that underlies typical hypogonadotrophic hypogonadism.

Authors

Sujatha A. Jayakody, Cynthia L. Andoniadou, Carles Gaston-Massuet, Massimo Signore, Anna Cariboni, Pierre M. Bouloux, Paul Le Tissier, Larysa H. Pevny, Mehul T. Dattani, Juan P. Martinez-Barbera

×

Figure 4

Reduced cell proliferation of RP periluminal progenitors in Hesx1Cre/+;Sox2fl/fl embryos.

Options: View larger image (or click on image) Download as PowerPoint
Reduced cell proliferation of RP periluminal progenitors in Hesx1Cre/+;S...
The region of the periluminal epithelium used for quantitative analysis is delineated in A–I. (A–D) Cyclin D2 immunofluorescence identifies cycling cells at the G1/S transition in RP, but not in the developing AP, at 12.5 and 14.5 dpc in both genotypes. (E) Quantitative analysis demonstrates a significant decrease in cycling cells in the mutant compared with the control pituitaries at both stages analyzed (12.5 dpc, **P = 0.0011; 14.5 dpc, ***P < 0.0001; Student’s t test). (F–I) BrdU immunodetection after a 90-minute pulse showing the presence of cycling cells in S phase mainly within the RP periluminal epithelium in both genotypes. PITX1 staining distinguishes pituitary tissue from surrounding mesenchyme. (J) There is a significant reduction in the percentage of BrdU+ cells from the total PITX1-stained nuclei in the mutant relative to the control pituitaries (12.5 dpc, *P = 0.0252; 14.5 dpc, ***P = 0.0001; Student’s t test). (K–L) BrdU and PITX1 double immunostaining on control (K) and mutant (L) pituitaries. BrdU was injected at 10.5 dpc and labeled cells traced at 14.5 dpc. In the control pituitary, BrdU labeling is strong in the rostral-tip and ventromedial region of the AP, weak in the dorsomedial region, and almost absent in the periluminal epithelium. In the mutant pituitary, BrdU retention in the periluminal epithelium is evident and a dorsomedial region of weak BrdU signal is not clearly observed. (M) There is a significant increase in BrdU retention in the mutant relative to the control pituitaries (*P = 0.0158; Student’s t test). Scale bars: 100 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts